Compare XPL & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XPL | MDXH |
|---|---|---|
| Founded | 1984 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Precious Metals | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.7M | 68.7M |
| IPO Year | 2000 | 2021 |
| Metric | XPL | MDXH |
|---|---|---|
| Price | $0.66 | $0.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $1.20 | ★ $7.67 |
| AVG Volume (30 Days) | 223.5K | ★ 227.0K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.78 |
| Revenue Next Year | N/A | $18.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.53 | $0.40 |
| 52 Week High | $0.98 | $5.33 |
| Indicator | XPL | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 42.29 | 40.18 |
| Support Level | $0.60 | $0.51 |
| Resistance Level | $0.80 | $0.75 |
| Average True Range (ATR) | 0.05 | 0.05 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 57.47 | 2.52 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.